BioSpace News Archive

Paragon 28, Inc., a leading orthopedic foot and ankle company, today announced the completion of a Series B financing.

Kalderos, the country’s first Drug Discount Manager, today announced it is now working with 3,000 340B covered entities through the Review tool in its Discount Monitoring solution, a revolutionary application that simplifies and streamlines collaboration on good faith inquiries for covered entities, ensuring compliance in the 340B Drug Pricing Program.

IDenta Corp. is a worldwide leader in the development of Field Detection and Home Diagnostics Testing Kits of Drugs & Explosives and Unique Forensic Products in the Homeland Security and Consumer Markets.

Micron Solutions, Inc. (OTCQB: MICR) (the “Company”), a diversified contract manufacturing organization, through its wholly-owned subsidiary, Micron Products, Inc., producing highly-engineered, innovative components requiring precision machining and injection molding, announced results for its second quarter ended June 30, 2020.

March of Dimes Inc. takes the protection and proper use of donor information very seriously. The organization was recently notified by one of its database providers, Blackbaud, of a security incident in which they stopped a ransomware attack.

Connecticut Biotech, a new innovative start-up company, is announcing the launch of its Secure Fit 3D-printed face mask frame. The mask frames are an exoskeleton worn outside of a traditional surgical mask, providing enhanced efficacy in protection against COVID-19 and other airborne pathogens. Secure Fit is a reusable, re

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or the “Group”, Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, is pleased to announce that it is anticipated that the Group’s will record a significant increase in its net profit attributable to the Shareholders for the six months ended 30 June 2020.

Cardax, Inc. (OTCQB:CDXI) reported its Q2 2020 results

Eve & Co Incorporated (the “Company” or “Eve & Co”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce its financial results for the three and six months ended June 30, 2020.

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) today announced business highlights and financial results for the fiscal year 2021 first quarter, ended June 30, 2020.